SeaStar Medical’s Chief Medical Officer Honored with 2026 Combat Nephrology Award
Event summary
- SeaStar Medical’s Chief Medical Officer, Col. (Ret.) Kevin Chung, MD, received the 2026 Combat Nephrology Award at the Update in Critical Care Nephrology meeting in Madrid, Spain.
- Dr. Chung’s award recognizes his contributions to renal support in extreme, high-acuity, trauma, and combat casualty environments.
- Dr. Chung’s keynote presentation, titled 'AKI in Military Operations: From Battlefield Experience to Future Strategies,' is scheduled for October 15, 2026.
- QUELIMMUNE therapy, approved in February 2024, showed a 77% survival rate in clinical trials, reducing mortality by approximately 50% compared to historical data.
- SeaStar Medical is conducting the NEUTRALIZE-AKI pivotal trial to evaluate the safety and efficacy of its SCD therapy in adults with AKI requiring continuous renal replacement therapy.
The big picture
SeaStar Medical’s recognition of Dr. Chung underscores the company’s focus on transformational treatments for critically ill patients facing organ failure. The Combat Nephrology Award highlights the bridge between military medicine and civilian critical care nephrology, positioning SeaStar Medical as a leader in innovative therapies for acute kidney injury. The ongoing NEUTRALIZE-AKI trial and the commercial success of QUELIMMUNE will be critical in determining the company’s long-term strategic position in the healthcare sector.
What we're watching
- Clinical Trial Progress
- The pace at which the NEUTRALIZE-AKI pivotal trial progresses will determine the broader applicability of SeaStar Medical’s SCD therapy beyond pediatric patients.
- Regulatory Approval
- Whether SeaStar Medical can secure additional regulatory approvals for its SCD therapy will impact its market expansion and revenue growth.
- Market Adoption
- How quickly QUELIMMUNE is adopted by top-ranked children’s medical centers will influence the company’s commercial success and market share.
Related topics
